Decoupling Bidirectional EphB/ephrinB2 in Multiple Myeloma

多发性骨髓瘤中双向 EphB/ephrinB2 的解偶联

• 批准号: 10407425
• 负责人: Joshua P Sasine
• 金额: $ 25.69万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10407425
• 关键词: Animals; Antibodies; Award; Binding Sites; Biology; Blood Cells; Blood Vessels; Bone Marrow; Bone Marrow Cells; Cancer Biology; Cancer Model; Cell Surface Receptors; Cell Therapy; Cells; Clinical; Clinical Research; Collaborations; Data; Dependence; Development; Development Plans; Disease; Disease Progression; Doctor of Philosophy; Endothelial Cells; Eph Family Receptors; Ephrin B Receptor; Ephrins; Event; Family; Family member; Foundations; Genetic Transcription; Goals; Growth; Hematologic Neoplasms; Hematopoietic Neoplasms; Hematopoietic stem cells; Human; Image; Immunologics; Impairment; Intervention; K-Series Research Career Programs; Knowledge; Laboratories; Lead; Life Expectancy; Ligands; Malignant - descriptor; Malignant Neoplasms; Mediating; Mediator of activation protein; Medical; Mentors; Mentorship; Multiple Myeloma; Mus; Outcome; PTK2 gene; Pathogenesis; Pathologic; Pathology; Patients; Pharmaceutical Preparations; Pharmacology; Phenotype; Plasma Cells; Population; Process; Proteins; Receptor Protein-Tyrosine Kinases; Recurrence; Relapse; Research; Research Training; Role; STAT3 gene; Scientist; Signal Pathway; Signal Transduction; Site-Directed Mutagenesis; Stimulus; Techniques; Testing; Therapeutic; Training; Vascular Endothelial Cell; Work; angiogenesis; arm; burden of illness; cancer cell; career; career development; cell behavior; cell motility; clinical care; design; experimental study; in vivo; in vivo evaluation; insight; knowledge base; novel therapeutics; preservation; programs; protective effect; skills; small hairpin RNA; stem cell biology; success; targeted treatment; tool; transcriptome sequencing; tumor progression

Project Summary/Abstract My research objectives are to study the impact of decoupling the EphB4/ephrinB2 axis in multiple myeloma (MM), a cancer of antibody-secreting plasma cells, and the mechanisms through which outcomes of decoupling occur. The Eph/ephrin family is the largest family of receptor tyrosine kinases. Eph/ephrin interactions mediate bidirectional signaling events in juxtaposed cells. Our preliminary studies suggest that Eph/ephrin interactions between MM and bone marrow endothelial cells (BMECs) are required for MM pathogenesis. MM is the most common primary bone marrow malignancy and although recent advances in treatment have prolonged the life expectancy of patients suffering with this disease, it remains incurable and inexorably fatal. Understanding of the biology of MM will reveal vulnerabilities that will lead to the development of targeted therapies for malignant plasma cells. Additionally, our preliminary studies regarding Eph/ephrin signaling provide important new insights into the pathological reciprocity of cancer cells and their microenvironmental neighbors. Here, we will use new tools to decouple the partnership of the Eph receptor/ephrin interaction. Historically, separating influences of such signaling events was less feasible. Now armed with advanced tools, we propose to dissect the bidirectionality inherent in this signaling pathway and provide a new insight into the pathological basis of MM. My primary short-term goals are to combine my scientific research and clinical care into a medically relevant and scientifically rigorous endeavor, while expanding my scientific skillset and progressing toward an independent research program. This award, training plan, and scientific aims are a critical step in the merger of my clinical and research training. I plan to lead a laboratory program dedicated to furthering the understanding of hematopoietic cancer pathology and discovering new therapeutic avenues. Long-term, I plan to become a leader in hematopoietic malignancies and cellular therapy. My training outline, mentorship plan, and scientific strategy are constructed to best reach my goals. This plan builds on my strong foundation in hematopoietic stem cell biology to transition into cancer biology. The career development plan includes expanding my skillset to include 1) building relevant in vivo cancer models; 2) didactic and hands-on training in developing an expanded knowledge base, scientific research tools, and techniques relevant to cancer biology; 3) transition to independence, supported by the completion of the aims of this award. This proposed track has already been initiated and the strong preliminary results, I believe, predict a high likelihood of success.

项目总结/摘要 我的研究目标是研究EphB 4/ephrinB 2轴解耦对多发性骨髓瘤的影响。 (MM)，一种分泌抗体的浆细胞的癌症，以及通过脱钩的结果的机制 发生. Eph/ephrin家族是受体酪氨酸激酶的最大家族。Eph/ephrin相互作用介导 并置细胞中的双向信号事件。我们的初步研究表明Eph/ephrin相互作用 MM发病机制需要MM和骨髓内皮细胞（BMEC）之间的相互作用。 MM是最常见的原发性骨髓恶性肿瘤，尽管最近的治疗进展 虽然延长了患有这种疾病的患者的预期寿命，但它仍然无法治愈， 致命的了解MM的生物学特性将揭示其漏洞，从而导致有针对性的 恶性浆细胞的治疗。此外，我们关于Eph/ephrin信号传导的初步研究提供了 重要的新见解的病理相互作用的癌细胞和他们的微环境邻居。 在这里，我们将使用新的工具来解耦Eph受体/ephrin相互作用的伙伴关系。从历史上看， 分离这些信号事件的影响不太可行。现在有了先进的工具，我们建议 剖析这种信号通路中固有的双向性，并提供一个新的见解， 根据MM 我的主要短期目标是将我的科学研究和临床护理联合收割机结合起来， 相关和科学严谨的奋进，同时扩大我的科学技能，并朝着一个 独立研究计划。该奖项，培训计划和科学目标是合并的关键一步， 我的临床和研究训练我计划领导一个致力于加深理解的实验室项目 研究造血系统癌症病理学并发现新的治疗途径。从长远来看，我计划成为一名 造血系统恶性肿瘤和细胞疗法的领导者。 我的培训大纲、指导计划和科学策略都是为了最好地实现我的目标而制定的。这 计划建立在我在造血干细胞生物学的坚实基础上，过渡到癌症生物学。的 职业发展计划包括扩展我的技能，包括1）建立相关的体内癌症模型; 2） 教学和实践培训，以发展扩大的知识基础，科学研究工具， 与癌症生物学相关的技术; 3）过渡到独立，通过完成目标的支持， 这个奖。这一拟议的轨道已经启动，我相信，初步结果表明， 成功的可能性很高。